Výsledky vyhledávání - "Victor, Sandor"

Plain Language Summary of Publication of the safety and efficacy of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene

Autor: Calum A MacRae, Matthew RG Taylor, Luisa Mestroni, John Moses, Euan A Ashley, Matthew T Wheeler, Neal K Lakdawala, Ray E Hershberger, Victor Sandor, Michael E Saunders, Colleen Oliver, Patrice A Lee, Daniel P Judge

Publikováno v: Future Cardiology. 19:55-63

What is this plain language summary about? This plain language summary describes the results of a study looking at the effects of a medicine called ARRY-371797 (also known as PF-07265803) in people with dilated cardiomyopathy (DCM for short) caused b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44c3ea9309bcacf880b826a8ce8c19a3
https://doi.org/10.2217/fca-2022-0099

Zobrazit plný text záznamu

Efficacy and Safety of ARRY-371797 in LMNA -Related Dilated Cardiomyopathy: A Phase 2 Study

Autor: Calum A. MacRae, Matthew R.G. Taylor, Luisa Mestroni, John Moses, Euan A. Ashley, Matthew T. Wheeler, Neal K. Lakdawala, Ray E. Hershberger, Victor Sandor, Michael E. Saunders, Colleen Oliver, Patrice A. Lee, Daniel P. Judge

Publikováno v: Circulation: Genomic and Precision Medicine. 16

Background: Lamin A/C gene ( LMNA )-related dilated cardiomyopathy is a serious and life-threatening condition with a high unmet medical need. This phase 2 study assessed the effects of the oral selective p38 mitogen-activated protein kinase inhibito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3aeab5997ddf9acce04c33abcd7949b6
https://doi.org/10.1161/circgen.122.003730

Zobrazit plný text záznamu

Efficacy and Safety of ARRY-371797 in

Autor: Calum A, MacRae, Matthew R G, Taylor, Luisa, Mestroni, John, Moses, Euan A, Ashley, Matthew T, Wheeler, Neal K, Lakdawala, Ray E, Hershberger, Victor, Sandor, Michael E, Saunders, Colleen, Oliver, Patrice A, Lee, Daniel P, Judge

Publikováno v: Circulation. Genomic and precision medicine.

Lamin A/C gene (Patients withTwelve patients were enrolled; median (minimum, maximum) 6-minute walk test distance at baseline was 314 (246, 412) m. At week 12, the mean (80% CI) increase from baseline in 6-minute walk test distance was 69 (39, 100) m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4715485df3f123627b4e0cc61d7f55df
https://pubmed.ncbi.nlm.nih.gov/36515663

Zobrazit plný text záznamu

Akademický článek

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Autor: Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek

Publikováno v: Haematologica, Vol 100, Iss 9 (2015)

Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared wit

Externí odkaz: https://doaj.org/article/bc698fc1152a4379840e4851a3e4dbc4

Zobrazit plný text záznamu

Akademický článek

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Publikováno v: Haematologica, Vol 100, Iss 4 (2015)

In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to place

Externí odkaz: https://doaj.org/article/7b14e5f72f2a48e1a0c3dbba240ffc5c

Zobrazit plný text záznamu

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Publikováno v: Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075

BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of path

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80ce4d5efea909032075f515edc5b20a
https://doi.org/10.1056/nejmoa1908075

Zobrazit plný text záznamu

Akademický článek

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Publikováno v: Haematologica, Vol 98, Iss 12 (2013)

COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis. This analysis of COMFORT-I describes the long-term efficacy a

Externí odkaz: https://doaj.org/article/eb6fdd88d68b49a881699bb335455fab

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání